Allogene Therapeutics, Inc. (ALLO) Covered Calls

You can sell covered calls on Allogene Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ALLO (prices last updated Mon 2:00 PM ET):

Allogene Therapeutics, Inc. (ALLO) Stock Quote
Last	Change	Bid	Ask	Volume	P/E	Market Cap
1.94	+0.07	1.93	1.94	1.9M	-	0.4

Covered Calls For Allogene Therapeutics, Inc. (ALLO)
Expiration	Strike	Call Bid	Net Debit	Return If Flat	Annualized Return If Flat
Jan 17	2	0.00	1.94	0.0%	0.0%
Feb 21	2	0.30	1.64	18.3%	110%
Subscribers get access to the full covered call chain, and more features.

Want to make money with covered calls? Sign Up For A Free Trial

Extended Business Description

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. It is also developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. Allogene Therapeutics, Inc. also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of AlloCAR T candidates across a portfolio of hematologic and solid tumors. The company was founded in 2017 and is headquartered in South San Francisco, California.

Top 10 Open Interest For Jan 17 Expiration				Top 5 High Yield
1.	NVDA covered calls	6.	INTC covered calls	1.	NMRA covered calls
2.	SLV covered calls	7.	SPY covered calls	2.	RGTI covered calls
3.	AAPL covered calls	8.	TSLA covered calls	3.	QBTS covered calls
4.	EEM covered calls	9.	IWM covered calls	4.	LUNR covered calls
5.	XLF covered calls	10.	TLT covered calls	5.	IONQ covered calls

Want more examples? ALLK Covered Calls | ALLT Covered Calls